Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Preventing Overdiagnosis of Nonalcoholic Fatty Liver Disease: Established Cutoff Values for Transient Elastography Are Needed.
Gastroenterology
March 2024
MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; Institute of Hepatology, Wenzhou Medical University, Wenzhou, China; Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China.
Screening for At-Risk Nonalcoholic Fatty Liver Disease in the Primary Care Setting.
Semin Liver Dis
May 2023
Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
While nonalcoholic fatty liver disease is a leading cause of end-stage liver disease, most patients with nonalcoholic fatty liver disease do not develop cirrhosis and its complications. Therefore, risk stratification using inexpensive, noninvasive screening modalities is critical to avoid overdiagnosis and overtreatment of a large proportion of the population. In this review, we discuss the data supporting screening and current professional society recommendations on this topic.
View Article and Find Full Text PDFOverdiagnosis of Nonalcoholic Fatty Liver Disease.
Am Fam Physician
December 2022
Jamaica Hospital Medical Center, Jamaica, New York.
Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis.
Ann Hepatol
January 2023
Houston Liver Institute, Houston, Texas. Electronic address:
Article Synopsis
- Type 2 Diabetes Mellitus (T2DM) often coexists with fatty liver disease, and a shift from using the term non-alcoholic fatty liver disease (NAFLD) to metabolic associated fatty liver disease (MAFLD) raises concerns about diagnosis accuracy.
- A study analyzing data from the NHANES survey found that the new MAFLD definition increased fatty liver diagnoses by nearly 69%, revealing significant health risks associated specifically with the MAFLD(+)/NAFLD(-) group.
- The premature adoption of MAFLD as a definition leads to over-diagnosis and worsens patient outcomes, highlighting the need for careful consideration in diagnosing and treating fatty liver in T2DM patients.
Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement.
Expert Rev Anticancer Ther
April 2022
Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
Introduction: Hepatocellular carcinoma (HCC) is a globally relevant medical problem. Fortunately, risk factors for this tumor have been identified, and surveillance protocols developed. Patients with liver cirrhosis have the highest risk of developing HCC and have historically been included in surveillance programs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!